Maritide

Maritide is a bispecific antibody-peptide conjugate that acts as a GIP receptor antagonist and GLP-1 receptor agonist. It is being investigated for its potential in treating obesity and metabolic disorders by modulating glucose metabolism and appetite.

In the literature, Maritide appears most often in work focused on weight loss, blood sugar and metabolism. Studies in this area tend to look at mechanisms and observed effects in laboratory and preclinical settings rather than outcomes in people, so the picture is best read as a map of where researchers have been curious — not as evidence of any benefit.

Because it is catalogued here under powder peptides, Maritide also shows up in discussions of appetite control. Coverage across those topics varies widely in quality and depth, and much of it is early-stage. Reading the underlying research directly is the only way to judge how strong any particular finding is.